HLS Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 23, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	87	84	87	220	338	367
Market Cap Growth	-3.67%	-3.35%	-60.57%	-34.93%	-7.74%	-32.63%
Enterprise Value	125	130	151	295	407	444
Last Close Price	2.60	2.56	2.50	6.41	9.55	10.24
PS Ratio	1.83	1.53	1.52	3.83	6.41	7.99
PB Ratio	1.66	1.22	0.98	1.88	2.39	2.65
P/FCF Ratio	7.50	10.87	6.09	13.92	23.48	48.18
P/OCF Ratio	7.40	10.85	6.08	13.88	23.41	47.99
EV/Sales Ratio	2.58	2.38	2.64	5.12	7.71	9.67
EV/EBITDA Ratio	8.42	8.99	7.74	15.14	19.78	26.32
EV/FCF Ratio	10.72	16.88	10.57	18.63	28.26	58.31
Debt / Equity Ratio	0.88	0.93	0.90	0.78	0.61	0.65
Debt / EBITDA Ratio	3.15	4.42	4.06	4.66	4.07	5.17
Debt / FCF Ratio	3.97	8.32	5.56	5.76	5.96	11.73
Net Debt / Equity Ratio	0.70	0.69	0.67	0.61	0.48	0.52
Net Debt / EBITDA Ratio	2.53	3.27	3.05	3.68	3.26	4.29
Net Debt / FCF Ratio	3.18	6.13	4.17	4.54	4.66	9.51
Asset Turnover	0.36	0.31	0.28	0.24	0.21	0.18
Inventory Turnover	2.13	1.58	1.43	1.20	0.99	1.43
Quick Ratio	0.81	1.11	1.22	1.02	1.18	0.93
Current Ratio	1.17	1.57	1.65	1.42	1.58	1.29
Return on Equity (ROE)	-20.02%	-23.25%	-24.69%	-16.50%	-7.95%	-8.82%
Return on Assets (ROA)	-1.86%	-2.60%	-2.87%	-3.26%	-1.35%	-2.42%
Return on Capital Employed (ROCE)	-4.00%	-5.60%	-5.70%	-6.40%	-2.50%	-4.50%
Earnings Yield	-13.79%	-22.63%	-28.70%	-10.03%	-3.41%	-3.42%
FCF Yield	13.33%	9.20%	16.42%	7.18%	4.26%	2.08%
Dividend Yield	-	-	2.74%	2.16%	1.46%	1.25%
Buyback Yield / Dilution	0.81%	1.31%	0.52%	-0.77%	-1.48%	-8.01%
Total Shareholder Return	0.81%	1.31%	3.26%	1.38%	-0.03%	-6.76%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.